We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: ALS
MedXY News
EnglishTag

ALS

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Statistical Inconsistency in ALS Trials: How Analysis Methods Skew Treatment Efficacy
NeurologyALSALSFRS-R

Statistical Inconsistency in ALS Trials: How Analysis Methods Skew Treatment Efficacy

By MedXY|Apr 24, 2026

A study reveals significant variability in ALSFRS-R analysis methods across 45 ALS trials, impacting treatment effect estimates and increasing false-positive risks, with implications for clinical decision-making and drug development.

PrimeC Combination Therapy Shows Potential to Slow Functional Decline in Amyotrophic Lateral Sclerosis: Insights from the PARADIGM Trial
NeurologyALSclinical trial

PrimeC Combination Therapy Shows Potential to Slow Functional Decline in Amyotrophic Lateral Sclerosis: Insights from the PARADIGM Trial

By MedXY|Mar 30, 2026

The Phase 2b PARADIGM trial demonstrates that PrimeC—a novel combination of celecoxib and ciprofloxacin—is safe and significantly slows functional decline in ALS patients over 18 months, offering new hope for multi-target neuroprotective st

PrimeC Shows Significant Long-term Functional Benefit and Reduced Mortality in ALS: Insights from the PARADIGM Trial
NeurologyALSclinical trials

PrimeC Shows Significant Long-term Functional Benefit and Reduced Mortality in ALS: Insights from the PARADIGM Trial

By MedXY|Mar 18, 2026

The Phase 2b PARADIGM trial reveals that PrimeC, a novel oral combination therapy, is safe and significantly slows functional decline and reduces the risk of death or hospitalization in ALS patients over 18 months.

Somatic Mosaicism in the Motor Cortex: A New Frontier in Understanding Sporadic ALS Pathogenesis
NeurologyALSFUS Protein

Somatic Mosaicism in the Motor Cortex: A New Frontier in Understanding Sporadic ALS Pathogenesis

By MedXY|Mar 12, 2026

This study identifies somatic gene mutations in excitatory neurons of the motor cortex as a potential driver of sporadic ALS, challenging the traditional view of the disease’s genetic origins.

Purine Biosynthetic Enzyme PAICS as a Central Mediator of DNA Damage and Cerebellar Atrophy in C9orf72-ALS
Clinical UpdatesALSC9orf72

Purine Biosynthetic Enzyme PAICS as a Central Mediator of DNA Damage and Cerebellar Atrophy in C9orf72-ALS

By MedXY|Mar 11, 2026

This review synthesizes recent evidence identifying PAICS downregulation as a critical link between C9orf72 loss-of-function, DNA repair failure, and cerebellar neurodegeneration, highlighting its potential as a therapeutic target.

“Off-the-Shelf” Allogeneic Regulatory T-Cell Therapy Shows Safety and Slows Functional Decline in ALS
Allergy & ImmunologyALSimmunotherapy

“Off-the-Shelf” Allogeneic Regulatory T-Cell Therapy Shows Safety and Slows Functional Decline in ALS

By MedXY|Dec 31, 2025

A Phase 1 trial published in NEJM Evidence demonstrates that allogeneic, umbilical cord-derived regulatory T cells are safe and potentially effective in slowing the progression of ALS, providing a scalable, off-the-shelf alternative to trad

Low-Dose Interleukin-2 as Adjunct to Riluzole in ALS: Insights from the Phase 2b MIROCALS Trial
Allergy & ImmunologyALSclinical trial

Low-Dose Interleukin-2 as Adjunct to Riluzole in ALS: Insights from the Phase 2b MIROCALS Trial

By MedXY|Dec 6, 2025

The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomark

Blood Test Breakthrough: Detecting ALS Over a Decade Before Symptoms Emerge
Medical NewsALSbiomarker

Blood Test Breakthrough: Detecting ALS Over a Decade Before Symptoms Emerge

By MedXY|Oct 6, 2025

New research identifies a protein signature in blood that detects ALS years before symptoms, challenging previous perceptions and offering hope for early diagnosis and intervention.

Trehalose in ALS: No Efficacy Shown in the HEALEY ALS Platform Trial
Clinical UpdatesALSclinical trial

Trehalose in ALS: No Efficacy Shown in the HEALEY ALS Platform Trial

By MedXY|Oct 1, 2025

Trehalose was safe but did not slow ALS progression compared to placebo in a large, adaptive phase 2/3 trial.

NeurologyALS

Breakthrough Alert! The Dawn of a New ALS Treatment Era—Pioneering Injection Administered at Peking University Third Hospital

By MedXY|Dec 25, 2025

A study reveals that negative online comments significantly increase anxiety and lower mood, especially in younger adults. Digital literacy, self-care, supportive communities, and platform moderation are vital to mitigate these effects. Add

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities